CN116322761A - 用拮抗性cd40单克隆抗体治疗自身免疫性疾病的方法 - Google Patents

用拮抗性cd40单克隆抗体治疗自身免疫性疾病的方法 Download PDF

Info

Publication number
CN116322761A
CN116322761A CN202180052235.3A CN202180052235A CN116322761A CN 116322761 A CN116322761 A CN 116322761A CN 202180052235 A CN202180052235 A CN 202180052235A CN 116322761 A CN116322761 A CN 116322761A
Authority
CN
China
Prior art keywords
ser
val
lys
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052235.3A
Other languages
English (en)
Chinese (zh)
Inventor
叶莹
U·阿拉斯
N·夏尔达
M·斯特拉瑟斯
K·普莱士
I·吉尔吉斯
A·弗拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN116322761A publication Critical patent/CN116322761A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180052235.3A 2020-08-25 2021-08-25 用拮抗性cd40单克隆抗体治疗自身免疫性疾病的方法 Pending CN116322761A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070209P 2020-08-25 2020-08-25
US63/070,209 2020-08-25
PCT/US2021/047610 WO2022046942A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
CN116322761A true CN116322761A (zh) 2023-06-23

Family

ID=77693641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052235.3A Pending CN116322761A (zh) 2020-08-25 2021-08-25 用拮抗性cd40单克隆抗体治疗自身免疫性疾病的方法

Country Status (11)

Country Link
US (1) US20230331860A1 (https=)
EP (1) EP4204099A1 (https=)
JP (1) JP2023539736A (https=)
KR (1) KR20230054451A (https=)
CN (1) CN116322761A (https=)
AU (1) AU2021331087A1 (https=)
BR (1) BR112023002803A2 (https=)
CA (1) CA3190727A1 (https=)
IL (1) IL300765A (https=)
MX (1) MX2023002093A (https=)
WO (1) WO2022046942A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018361743A1 (en) * 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Also Published As

Publication number Publication date
AU2021331087A1 (en) 2023-04-20
MX2023002093A (es) 2023-03-15
JP2023539736A (ja) 2023-09-19
WO2022046942A1 (en) 2022-03-03
BR112023002803A2 (pt) 2023-03-14
IL300765A (en) 2023-04-01
CA3190727A1 (en) 2022-03-03
EP4204099A1 (en) 2023-07-05
US20230331860A1 (en) 2023-10-19
KR20230054451A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
KR102627246B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
JP7285936B2 (ja) Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
JP6703520B2 (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
KR102713355B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
US8367063B2 (en) Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
JP2022050388A (ja) ヒトｃｄ３８に対する抗体
CN106061999B (zh) Il-21抗体
EP2583980A1 (en) Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
JP6825033B2 (ja) Ｂａｆｆ及びｂ７ｒｐ１に特異的なタンパク質及びその使用
JP2019500862A (ja) Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
CN103635490A (zh) 用作治疗剂的可溶性蛋白
AU3369701A (en) Antibodies to human il-1beta
JP2023080074A (ja) 抗ｔｒｅｍ－１抗体およびその使用
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
WO2021018035A1 (zh) 人源化抗il17a抗体及其应用
KR20230034960A (ko) Lag3에 결합하는 항체 및 그 용도
KR20240046224A (ko) 이중특이성 항체 및 그 용도
JP2023532248A (ja) 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用
CN116322761A (zh) 用拮抗性cd40单克隆抗体治疗自身免疫性疾病的方法
TW202136306A (zh) 用於治療實性瘤的靶向間皮素的ｃｄ４０激動性多特異性抗體構建體
HK40104821A (zh) 人cd30配体抗原结合蛋白
EA051986B1 (ru) Антигенсвязывающий белок и слитый белок, его содержащий
HK40066235B (zh) 人源化抗il17a抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination